Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1Phase 1 1

Status

Withdrawn 1Terminated 1Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 4NETWORK 1

Study Type

Interventional 5Observational 1

Sponsor

Cancer Type

CNS 5

Conditions

Glioblastoma 5Recurrence 4Head and Neck Neoplasms 3Diffuse Intrinsic Pontine Glioma 3Glioma 2Brain Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Recurrence of Head and Cancer in Irraiated Area 1Pelvic Neoplasms 1Pancreatic Neoplasms 1Nasopharyngeal Neoplasms 1Nasopharyngeal Diseases 1Nasopharyngeal Carcinoma 1Central Nervous System Neoplasms 1Carcinoma, Squamous Cell 1Breast Cancer Recurrent 1Brain Stem Neoplasms 1

Interventions

Temozolomide 393Radiotherapy 196Bevacizumab 156Radiation 77Magnetic Resonance Spectroscopy 68Lomustine 47Surgical Procedures, Operative 42Carmustine 41pembrolizumab 39Irinotecan 38Nivolumab 32Specimen Handling 27Carboplatin 27Radiosurgery 24Erlotinib Hydrochloride 24Chemotherapy, Adjuvant 23Radiotherapy, Intensity-Modulated 22Drug Therapy 21Cyclophosphamide 20Aminolevulinic Acid 20O(6)-benzylguanine 17sargramostim 16Radiotherapy, Conformal 15temsirolimus 14Granulocyte-Macrophage Colony-Stimulating Factor 14Everolimus 14Vorinostat 13Sorafenib 13poly ICLC 12atezolizumab 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Interventional × Glioblastoma × Re-Irradiation × Clear all
NCT01743950 2026-03-25

A Phase II Study of Pulse Reduced Dose Rate Radiation Therapy With Bevacizumab

University of Wisconsin, Madison

Phase 2 Terminated
49 enrolled 19 charts
CNS

Glioblastoma, Glioma

NCT05904119 2026-02-17

LEGATO

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3 Recruiting
411 enrolled
CNS

Glioblastoma

NCT03743662 2026-01-07

Nivolumab With Radiation Therapy and Bevacizumab for Recurrent MGMT Methylated Glioblastoma

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
39 enrolled
CNS

Glioblastoma

NCT03661723 2024-09-19

Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma

Dana-Farber Cancer Institute

Phase 2 Completed
60 enrolled 23 charts
CNS

Glioblastoma

NCT05666349 2024-03-26

RiNG

University College, London

Phase 1 Withdrawn
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡